Table 2 Characteristic of the patient’s groups based on TgAb response (N = 76)
| Variables |
Incomplete response (N = 48, 63.2%) | Excellent response (N = 28, 36.8%) |
Total (N = 76) | P-value |
|---|---|---|---|---|
| aAge (Years) | 37.75 ± 14.96 | 32.21 ± 11.66 | 35.71 ± 14.01 | 0.077 |
| Sex (Female) | 40 (83.3) | 23 (82.1) | 63 (82.9) | 0.990 |
| $TgAb (baseline) | 1071.27 ± 1216.17 | 99.61 ± 91.29 | 713.29 ± 1073.55 | < 0.001 |
| Surgery | ||||
| CCLND (Yes) | 41 (85.4) | 18 (64.3) | 59 (77.6) | 0.033 |
| LLND (Yes) | 27 (56.3) | 8 (28.6) | 35 (46.1) | 0.020 |
| Histopathology | ||||
| HPE CCLND (Yes) | 34 (70.8) | 13 (46.4) | 47 (61.8) | 0.035 |
| HPLND (Yes) | 20 (41.7) | 6 (21.4) | 26 (34.2) | 0.073 |
| Pathology | ||||
| PCT | 43 (89.6) | 26 (92.8) | 69 (90.8) | 0.991 |
| PCT FV | 3 (6.3) | 2 (7.1) | 5 (6.6) | |
| FCT | 1 (2.1) | 1 (3.6) | 2 (2.6) | |
| T stage | ||||
| 1 | 3 (6.3) | 6 (21.4) | 9 (11.8) | 0.228 |
| 2 | 9 (18.8) | 4 (14.3) | 13 (17.1) | |
| 3 | 7 (14.6) | 5 (17.9) | 12 (15.8) | |
| X | 29 (60.4) | 13 (46.4) | 42 (55.3) | |
| N Stage | ||||
| 0 | 7 (14.6) | 13 (46.4) | 20 (26.3) | 0.010 |
| N1a | 16 (33.3) | 9 (32.1) | 25 (32.9) | |
| N1b | 22 (45.8) | 5 (17.9) | 27 (35.5) | |
| X | 3 (6.3) | 1 (3.6) | 4 (5.3) | |
| AJCC staging | ||||
| 1 | 39 (81.3) | 27 (96.4) | 66 (86.8) | 0.0345 |
| 2 | 7 (14.6) | 1 (3.6) | 8 (10.5) | |
| 3 | 2 (4.1) | 0 (0) | 1 (2.7) | |
| WBS findings | ||||
| Positive | 42 (87.5) | 26 (92.8) | 68 (89.5) | 0.703 |
| Remnant only (Yes) | 38 (79.1) | 21 (75.0) | 59 (77.6) | 0.519 |
| LN on WBS | 10 (20.8) | 7 (25.0) | 17 (22.4) | 0.674 |
| LN Metastases b(Yes) | 39 (81.5) | 17 (60.7) | 56 (73.7) | 0.005 |